The Senate 340B Working Group is seeking additional stakeholder input on key longstanding issues surrounding the federal drug discount program as it floats draft bipartisan legislation to clarify the program’s intent by preventing drug companies from imposing contract pharmacy restrictions, requiring that off-site locations be wholly owned and completely integrated with the operations of a 340B covered entity before they can participate in the program, cementing an official definition of a 340B “patient” and establishing a user fee program to...